We take Russian scientific R&D and turn it into market-ready businesses, then sell them to strategic buyers. Every project passes through our 3E filter: Ecology → Emotions → Economy. Parent structure in Singapore, R&D in Russia.
Every portfolio project passes this check before receiving the studio's capital and resources — a working selection criterion, not a slogan.
Nature-like technologies and biotech that reduce humanity's footprint on the planet. For PolyGate this is literal: solvent-free mechanochemical synthesis instead of classical chemistry.
A healthy environment leads to healthier, happier people — from insulin tablets instead of injections to safe antidotes that don't require hospitalization.
Happier people are more creative — they build new technologies and drive economic efficiency. The studio's goal: at least 3 successful exits in 5 years.
We build companies on proven science, bring them to product quality through our own ARCHITECT, and sell them to strategic buyers.
Tablets instead of injections for type 1 diabetes. Active only at elevated glucose levels — does not induce hypoglycemia at normal blood sugar.
↓ up to 78% glucose, preclinicalThe chitosan-isoniazid complex boosts and de-risks standard tuberculosis therapy.
3× activity (1 µg/ml vs. 3), 2–4× lower doseCarbon monoxide antidote, no injections or hospitalization — for emergency services and industrial safety. No trade name of its own yet; "Acizol" is a different, existing reference product, not ours.
Active in 30 min, 6× longer in blood, 20× safety marginPick what's relevant — the offer and next step differ by audience.
Don't buy a drug — buy a platform. Licensing PolyGate opens access to three product lines at once.
Discuss a license →We built ARCHITECT for ourselves — so we wouldn't make mistakes screening our own venture projects. TRL, market-potential, and freedom-to-operate scoring for your own R&D projects.
Set up a pilot →The same system we use to screen our own projects — applied to a pipeline of external grant applications. ARCHITECT's scaling direction.
Discuss a pilot →If you have research without a business wrapper, we take on capitalization, legal structure, and the path to exit.
Tell us about it →A real scientific asset with preclinical data and an experienced engineering implementation partner (FB Consult) — not another pilot that goes nowhere.
Join us →